BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
34.24
+0.39 (1.15%)
Apr 17, 2025, 4:00 PM EDT - Market closed
BridgeBio Pharma Employees
As of December 31, 2024, BridgeBio Pharma had 730 total employees, including 725 full-time and 5 part-time employees. The number of employees increased by 174 or 31.29% compared to the previous year.
Employees
730
Change (1Y)
174
Growth (1Y)
31.29%
Revenue / Employee
$303,975
Profits / Employee
-$733,921
Market Cap
6.44B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
BBIO News
- 7 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 18 days ago - Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM - GlobeNewsWire
- 22 days ago - Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug - Benzinga
- 22 days ago - Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM - GlobeNewsWire
- 25 days ago - BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions - GlobeNewsWire
- 4 weeks ago - BridgeBio Announces CFO Succession - GlobeNewsWire
- 7 weeks ago - BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt - GlobeNewsWire
- 7 weeks ago - BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt - GlobeNewsWire